AIM: To evaluate whether hypofractionation with integrated boost to the tumour bed using intensity-modulated radiation therapy is an acceptable option and to determine whether this treatment compromises local control, toxicity and cosmesis. BACKGROUND: Retrospective studies have demonstrated that patients who are treated with HF and integrated boost experience adequate local control, a dosimetric benefit, decreased toxicity and acceptable cosmesis compared with conventional fractionation. MATERIALS AND METHODS: A retrospective, observational and longitudinal study was conducted from January 2008 to June 2015 and included 34 patients with breast cancer (stage 0-II) who were undergoing conservative surgery.The prescribed doses were 45 Gy in 20 fractions (2.25 Gy/fraction) to the breast and 56 Gy in 20 fractions (2.8 Gy/fraction) to the tumour bed. RESULTS: Thirty-four patients were included. The mean follow-up was 49.29 months, and the mean age was 52 years. The mean percentage of PTV from the mammary region that received 100% of the prescribed dose was 97.89% (range 95-100), and the mean PTV percentage of the tumour bed that received 100% of the dose was 98% (95-100).The local control and the overall survival were 100%, and the cosmesis was good in 82% of the patients. Grade 1 acute toxicity was present in 16 patients (47%), and grade 1 chronic toxicity occurred in 6 cases (18%). CONCLUSION: The results of the present study demonstrate that hypofractionation with integrated boost using intensity-modulated radiation therapy is an acceptable option that provides excellent local control and low toxicity.
AIM: To evaluate whether hypofractionation with integrated boost to the tumour bed using intensity-modulated radiation therapy is an acceptable option and to determine whether this treatment compromises local control, toxicity and cosmesis. BACKGROUND: Retrospective studies have demonstrated that patients who are treated with HF and integrated boost experience adequate local control, a dosimetric benefit, decreased toxicity and acceptable cosmesis compared with conventional fractionation. MATERIALS AND METHODS: A retrospective, observational and longitudinal study was conducted from January 2008 to June 2015 and included 34 patients with breast cancer (stage 0-II) who were undergoing conservative surgery.The prescribed doses were 45 Gy in 20 fractions (2.25 Gy/fraction) to the breast and 56 Gy in 20 fractions (2.8 Gy/fraction) to the tumour bed. RESULTS: Thirty-four patients were included. The mean follow-up was 49.29 months, and the mean age was 52 years. The mean percentage of PTV from the mammary region that received 100% of the prescribed dose was 97.89% (range 95-100), and the mean PTV percentage of the tumour bed that received 100% of the dose was 98% (95-100).The local control and the overall survival were 100%, and the cosmesis was good in 82% of the patients. Grade 1 acute toxicity was present in 16 patients (47%), and grade 1 chronic toxicity occurred in 6 cases (18%). CONCLUSION: The results of the present study demonstrate that hypofractionation with integrated boost using intensity-modulated radiation therapy is an acceptable option that provides excellent local control and low toxicity.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Kevin S Oh; Feng-Ming Kong; Kent A Griffith; Beth Yanke; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-25 Impact factor: 7.038
Authors: Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-16 Impact factor: 7.038
Authors: Mark W McDonald; Karen D Godette; Daisy J Whitaker; Lawrence W Davis; Peter A S Johnstone Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-21 Impact factor: 7.038
Authors: Gary M Freedman; Penny R Anderson; Richard J Bleicher; Samuel Litwin; Tianyu Li; Ramona F Swaby; Chang-Ming Charlie Ma; Jinsheng Li; Elin R Sigurdson; Deborah Watkins-Bruner; Monica Morrow; Lori J Goldstein Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-12 Impact factor: 7.038
Authors: Vasileios Askoxylakis; Alexandra D Jensen; Matthias F Häfner; Leonie Fetzner; Florian Sterzing; Joerg Heil; Christof Sohn; Johannes Hüsing; Uta Tiefenbacher; Frederik Wenz; Jürgen Debus; Holger Hof Journal: BMC Cancer Date: 2011-06-15 Impact factor: 4.430